Novel Biomarkers for Personalized Cancer Immunotherapy

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2019 Aug 25

PMID 31443339

Citations 24

Authors

Yoshitaro Shindo

Shoichi Hazama

Ryouichi Tsunedomi

Nobuaki Suzuki

Hiroaki Nagano

Affiliations

Soon will be listed here.

Abstract

Cancer immunotherapy has emerged as a novel and effective treatment strategy for several types of cancer. Immune checkpoint inhibitors (ICIs) have recently demonstrated impressive clinical benefit in some advanced cancers. Nonetheless, in the majority of patients, the successful use of ICIs is limited by a low response rate, high treatment cost, and treatment-related toxicity. Therefore, it is necessary to identify predictive and prognostic biomarkers to select the patients who are most likely to benefit from, and respond well to, these therapies. In this review, we summarize the evidence for candidate biomarkers of response to cancer immunotherapy.

Citing Articles

Fluorescence Lifetime Imaging of NAD(P)H in Patients' Lymphocytes: Evaluation of Efficacy of Immunotherapy.

Yuzhakova D, Sachkova D, Izosimova A, Yashin K, Yusubalieva G, Baklaushev V Cells. 2025; 14(2.

PMID: 39851525 PMC: 11764258. DOI: 10.3390/cells14020097.

Resistance mechanisms to immune checkpoint inhibitors: updated insights.

Alsaafeen B, Ali B, Elkord E Mol Cancer. 2025; 24(1):20.

PMID: 39815294 PMC: 11734352. DOI: 10.1186/s12943-024-02212-7.

Next-Generation Immunotherapy: Advancing Clinical Applications in Cancer Treatment.

Garg P, Pareek S, Kulkarni P, Horne D, Salgia R, Singhal S J Clin Med. 2024; 13(21).

PMID: 39518676 PMC: 11546714. DOI: 10.3390/jcm13216537.

Immunohistochemical study of Programmed Cell Death Ligand 1 (PDL1) expression by combined positive score using 22C3 clone in head and neck squamous cell carcinomas, its correlation with clinicopathological features and outcome.

Gangadhar P, Ilanthodi S, Shetty R, Shenoy K, Philipose T J Oral Maxillofac Pathol. 2024; 28(1):29-36.

PMID: 38800420 PMC: 11126244. DOI: 10.4103/jomfp.jomfp_339_23.

Immunodiagnosis - the promise of personalized immunotherapy.

Wang R, Xiong K, Wang Z, Wu D, Hu B, Ruan J Front Immunol. 2023; 14:1216901.

PMID: 37520576 PMC: 10372420. DOI: 10.3389/fimmu.2023.1216901.

References

Mansfield A, Aubry M, Moser J, Harrington S, Dronca R, Park S . Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. Ann Oncol. 2016; 27(10):1953-8. PMC: 5035793. DOI: 10.1093/annonc/mdw289. View

Nielsen M, Lund O, Buus S, Lundegaard C . MHC class II epitope predictive algorithms. Immunology. 2010; 130(3):319-28. PMC: 2913211. DOI: 10.1111/j.1365-2567.2010.03268.x. View

Halvorsen A, Sandhu V, Sprauten M, Flote V, Kure E, Brustugun O . Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab. Acta Oncol. 2018; 57(9):1225-1231. DOI: 10.1080/0284186X.2018.1465585. View

Inomata M, Hirai T, Seto Z, Tokui K, Taka C, Okazawa S . Clinical Parameters for Predicting the Survival in Patients with Squamous and Non-squamous-cell NSCLC Receiving PD-1 Inhibitor Therapy. Pathol Oncol Res. 2018; 26(1):327-333. DOI: 10.1007/s12253-018-0473-x. View

Maeda N, Yoshimura K, Yamamoto S, Kuramasu A, Inoue M, Suzuki N . Expression of B7-H3, a potential factor of tumor immune evasion in combination with the number of regulatory T cells, affects against recurrence-free survival in breast cancer patients. Ann Surg Oncol. 2014; 21 Suppl 4:S546-54. PMC: 4236607. DOI: 10.1245/s10434-014-3564-2. View

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky J, Desrichard A . Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23):2189-2199. PMC: 4315319. DOI: 10.1056/NEJMoa1406498. View

Hazama S, Tamada K, Yamaguchi Y, Kawakami Y, Nagano H . Current status of immunotherapy against gastrointestinal cancers and its biomarkers: Perspective for precision immunotherapy. Ann Gastroenterol Surg. 2018; 2(4):289-303. PMC: 6036392. DOI: 10.1002/ags3.12180. View

Yarchoan M, Johnson 3rd B, Lutz E, Laheru D, Jaffee E . Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer. 2017; 17(4):209-222. PMC: 5575801. DOI: 10.1038/nrc.2016.154. View

Turcotte S, Gros A, Tran E, Lee C, Wunderlich J, Robbins P . Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy. Clin Cancer Res. 2013; 20(2):331-43. PMC: 3927404. DOI: 10.1158/1078-0432.CCR-13-1736. View

10.

Muro K, Chung H, Shankaran V, Geva R, Catenacci D, Gupta S . Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016; 17(6):717-726. DOI: 10.1016/S1470-2045(16)00175-3. View

11.

Topalian S, Taube J, Anders R, Pardoll D . Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016; 16(5):275-87. PMC: 5381938. DOI: 10.1038/nrc.2016.36. View

12.

Kijima T, Hazama S, Tsunedomi R, Tanaka H, Takenouchi H, Kanekiyo S . MicroRNA-6826 and -6875 in plasma are valuable non‑invasive biomarkers that predict the efficacy of vaccine treatment against metastatic colorectal cancer. Oncol Rep. 2016; 37(1):23-30. PMC: 5355687. DOI: 10.3892/or.2016.5267. View

13.

Iorio M, Ferracin M, Liu C, Veronese A, Spizzo R, Sabbioni S . MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65(16):7065-70. DOI: 10.1158/0008-5472.CAN-05-1783. View

14.

Rubinstein M, Wang X, Liu W, Hao Y, Cai G, Han Y . Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe. 2013; 14(2):195-206. PMC: 3770529. DOI: 10.1016/j.chom.2013.07.012. View

15.

Blackburn S, Shin H, Nicholas Haining W, Zou T, Workman C, Polley A . Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2008; 10(1):29-37. PMC: 2605166. DOI: 10.1038/ni.1679. View

16.

Shindo Y, Yoshimura K, Kuramasu A, Watanabe Y, Ito H, Kondo T . Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor. Anticancer Res. 2015; 35(1):129-36. View

17.

Rosenberg S, Packard B, Aebersold P, Solomon D, Topalian S, TOY S . Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988; 319(25):1676-80. DOI: 10.1056/NEJM198812223192527. View

18.

Breitkreutz I, Podar K, Figueroa-Vazquez V, Wilhelm S, Hayden P, Anderson K . The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma. Ann Hematol. 2018; 97(5):839-849. DOI: 10.1007/s00277-018-3237-5. View

19.

Herbst R, Baas P, Kim D, Felip E, Perez-Gracia J, Han J . Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015; 387(10027):1540-1550. DOI: 10.1016/S0140-6736(15)01281-7. View

20.

Pages F, Mlecnik B, Marliot F, Bindea G, Ou F, Bifulco C . International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018; 391(10135):2128-2139. DOI: 10.1016/S0140-6736(18)30789-X. View